Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$1.46 USD
-0.19 (-11.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.50 +0.04 (2.74%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NMRA 1.46 -0.19(-11.52%)
Will NMRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neumora Stock Hits Record Low on Depression Drug Study Failure
Other News for NMRA
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Q2 2025 Neumora Therapeutics Inc Earnings Call Transcript
Neumora Therapeutics GAAP EPS of -$0.33
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c)